Table 3: Efficacy results of VICTOR trial in the TNBC population.

VariableOverall

Clinical benefit rate (CR + PR + SD ≥ 24 weeks) (%)10/28 (35.7)
[18.6–55.9]
Kaplan-Meier estimate of median duration of clinical benefit (months)11.3
Disease control rate (CR + PR + SD) 15/28 (53.6%)
Kaplan-Meier estimate of median duration of response in disease control (months)7.4
Kaplan-Meier estimate of median PFS (months)4.7